polyarticular juvenile idiopathic arthritisrheumatoid factor-positive polyarticular juvenile idiopathic arthritis+1 moreTrials & approvals
AbbVie receives EU approval for a new pediatric indication of its drug, providing an oral treatment option for young patients with polyarticular juvenile idiopathic arthritis (pJIA). This expands the therapeutic options available for this patient population.
New indication adds oral option for young patients
Original title: “AbbVie wins EU approval for paediatric pJIA use”